Gianluca Cuomo1, Vanni Borghi2, Pietro Andreone3, Marco Massari4, Erica Villa5, Antonello Pietrangelo6, Gabriella Verucchi7, Carlo Ferrari8. 1. Infectious Disease, Azienda Ospedaliero Universitaria di Modena, Modena, Italy. Electronic address: gian.cuomo@gmail.com. 2. Infectious Disease, Azienda Ospedaliero Universitaria di Modena, Modena, Italy. 3. Internal Medicine, Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy. 4. Infectious Disease, IRCCS - ASMN Reggio Emilia, Reggio Emilia, Italy. 5. Gastroenterology, Azienda Ospedaliero Universitaria di Modena, Italy. 6. Internal Medicine, Azienda Ospedaliero Universitaria Modena, Modena, Italy. 7. Infectious Disease, Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy. 8. Infectious Disease and Hepatology, Azienda Ospedaliero Universitaria di Parma, Parma, Italy.
Abstract
BACKGROUND AND AIMS: Very little is known about the access to treatment for Chronic Hepatitis B in the real clinical practice and the characteristics of the patients who do not receive antiviral therapy. METHODS: HBV-RER is an observational multicenter network that collected data of patients with HBV infection during a 3 years observational period (2009-2012). RESULTS: Among 2527 HBsAg positive patients, 1099 were never treated (NT); only 280 were included in the analysis due to different exclusion causes A minority was HBeAg-positive. The median age was 42. At liver biopsy most patients had Metavir score of F0-F1. Univariate analysis between 280 NT patients and the 290 naïve to treatment showed that NT patients were mostly female (P=0.002), not Italian (P=0.044), younger (P<0.001). Metavir score was lower in NT (P0.002), such as the Fib4 score (P<0.001). HBV DNA level was significantly higher in NT. At multivariate analysis, independent variables associated with no-treatment were younger age, female gender, Metavir score F0-F1, Fib4 lower than 1.6 and lower blood level of HBV-DNA. CONCLUSIONS: There is a large number of patients eligible to treatment who do not receive it. A younger age and a less severe disease seem to be associated to deferral of treatment.
BACKGROUND AND AIMS: Very little is known about the access to treatment for Chronic Hepatitis B in the real clinical practice and the characteristics of the patients who do not receive antiviral therapy. METHODS: HBV-RER is an observational multicenter network that collected data of patients with HBV infection during a 3 years observational period (2009-2012). RESULTS: Among 2527 HBsAg positive patients, 1099 were never treated (NT); only 280 were included in the analysis due to different exclusion causes A minority was HBeAg-positive. The median age was 42. At liver biopsy most patients had Metavir score of F0-F1. Univariate analysis between 280 NT patients and the 290 naïve to treatment showed that NT patients were mostly female (P=0.002), not Italian (P=0.044), younger (P<0.001). Metavir score was lower in NT (P0.002), such as the Fib4 score (P<0.001). HBV DNA level was significantly higher in NT. At multivariate analysis, independent variables associated with no-treatment were younger age, female gender, Metavir score F0-F1, Fib4 lower than 1.6 and lower blood level of HBV-DNA. CONCLUSIONS: There is a large number of patients eligible to treatment who do not receive it. A younger age and a less severe disease seem to be associated to deferral of treatment.
Authors: Daan W Von den Hoff; Floor A C Berden; Femke Atsma; Arnt F A Schellekens; Joost P H Drenth Journal: J Clin Med Date: 2022-02-21 Impact factor: 4.241